CNTNAP1 Neuropathy Models for Axonal Domain Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are lacking for neuropathies caused by CNTNAP1 mutations, which result in severe consequences such as slowed nerve conduction, intellectual disability, muscle atrophy, and high infant mortality due to dysregulation and disorganization of axonal domains.
Innovation Solution
Development of transgenic mouse models and methods for screening active agents, including the use of lentiviruses to overexpress wild-type CNTNAP1 in neurons to restore proper domain organization and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered, then the natural progression of the disease continues with severe consequences, but there are no therapeutic options available
Solution Approach 1:
The patent applies preliminary action by establishing transgenic mouse models with CNTNAP1 mutations before disease progression occurs, enabling pre-clinical testing and early intervention strategies. The models allow screening for active agents before the disease reaches severe stages, preventing rather than merely treating the condition.
Solution Approach 2:
The patent uses transgenic mouse models as intermediaries between the known CNTNAP1 mutation and potential human treatments. These models serve as a bridge system to test therapeutic agents and mechanisms that can then be translated to human therapy, providing an intermediary platform for drug development.
2Object-generated harmful factors
If CNTNAP1 mutations occur, then axonal domain organization becomes disorganized, but the specific molecular mechanisms remain poorly characterized
Solution Approach 1:
The patent applies local quality by focusing on specific axonal domains (nodes, paranodes, juxtaparanodes) and characterizing the localized effects of CNTNAP1 mutations in each region. The transgenic models enable detailed examination of domain-specific disorganization and molecular mechanisms at particular locations along the axon rather than treating the entire system uniformly.
3Ease of operation
If conventional therapies are used, then general neuropathy symptoms may be addressed, but CNTNAP1-specific mechanisms are not targeted
Solution Approach 1:
The patent applies parameter changes by using transgenic mouse models to systematically vary and test different therapeutic parameters (drug candidates, dosages, timing) specifically for CNTNAP1 mutation mechanisms. This enables optimization of treatment parameters tailored to the specific molecular pathology rather than using general neuropathy protocols.
Data Source
AI summary
Disclosed herein are methods and compositions useful in treating a neuropathy caused by a CNTNAP1 mutation. Transgenic animal models and cell lines are disclosed for the study of neuropathies caused by a CNTNAP1 mutation. Methods of screening and identifying active agents for the treatment of neuropathies caused by a CNTNAP1 mutation are also provided.